The in-utero metabolic environment is now a widely researched and well established focus in the study of the developmental ...

In line with previous progress reports by Countdown to 2030 for Women's, Children's, and Adolescents' Health, this report analyses global and regional trends and inequalities in health determinants, ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Novo Nordisk failed to impress the market with late-stage clinical trial data for CagriSema, an anti-obesity candidate, but it has more potential gems in its pipeline. Novo Nordisk and Eli Lilly ...

The Global equity markets ended the fourth quarter of 2024 on a subdued note after reaching a high in the wake of the U.S. presidential election. The Harbor International Compounders Fund returned ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.